Serum Level of IL31,33 and 36 in Egyptian Paients With Psoriasis

NCT04344574 | Unknown

• 1 other identifier: interleukins in psoriasis
• Study Type: observational
• Target: 90
• Locations: 0 countries
• Sites: N/A

Brief Summary

Evaluating Serum Level Of IL 31 , IL33 and IL36 and Their Correlation with Disease Activity In Patients With Psoriasis In Assuit University Hospital .

• To correlate their levels with disease activity using PASI score .
• To allow better understanding of the pathophysiological mechanism of the disease .

Conditions

Psoriasis

Keywords

interleukine 31,33 and 36

Outcome Measures

Primary Outcomes (2)

• describe the serum levels of IL31, IL33 and IL36 in egyptian patients with psoriasis.

  1. Blood samples will collected from psoriatic patients and controls. 2. using ELISA kits to measure serum concentration of IL31 \[pg/ml\] , IL33 \[pg/ml\] and IL36 \[pg/ml\] . 3. p value less than 0,05 reflect significant increase in serum levels of measured interleukins.

  Baseline

• 4. Knowing the extent of disease activity by Psoriasis Area and Severity Index (PASI) score.

  assessment of the severity of lesions and the area affected into a single score in the range 0 (no disease) to 72 (maximal disease).

  Baseline

Secondary Outcomes (1)

• serum level of interleukins reflect severity of disease and represent anovel target for antipsoriatic drug theraby.

  Baseline

Eligibility Criteria

• Sex: all
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

study will be performed on 45 psoriasis patients and 45 healthy matched volunteers without a family history of psoriasis and other autoimmune as well as inflammatory diseases and underwent no systemic treatment including glucocorticoids, immunosuppressive drugs, or phototherapy at least 1 month before the PASI score ,evaluation and sample collection period . All patients will be recruited from the Psoriasis Clinic in Dermatology Department of Assuit University Hospital

You may qualify if:

• Patients with all types of psoriasis.
• healthy volunteers without a family history of psoriasis or other autoimmune disease.

You may not qualify if:

• other autoimmune , other chronic inflammatory or systemic diseases.
• cases received glucocorticoids, immunosuppressive drugs at least 1 month before sample collection .

Sponsors & Collaborators

• Assiut University: lead

MeSH Terms

Conditions

Psoriasis

Condition Hierarchy (Ancestors)

Skin Diseases, Papulosquamous; Skin Diseases; Skin and Connective Tissue Diseases

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: April 1, 2020
• First Posted: April 14, 2020
• Study Start: June 1, 2020
• Primary Completion: June 1, 2021
• Study Completion: July 1, 2021
• Last Updated: April 14, 2020

Record last verified: 2020-04